About Us | Contact Us

As a result of millions of goods lacking child-resistant packaging, Pfizer recalls the migraine medication Nurtec ODT.

Consumers of Nurtec ODT, a prescription headache medicine that was recalled for failing to meet safety standards in its packaging, are receiving child-resistant pouches from Pfizer, the firm and the U.S. Consumer Product Safety Commission announced on Thursday.

Orally disintegrating Nurtec ODT (rimegepant) 75mg tablets sold in packs of eight on a blister card are included in the recall. According to the website for Nurtec ODT, this medicine is used to both treat acute migraine attacks and prevent episodic migraine in adults.

The medication’s container “is not child resistant, posing a risk of poisoning if the contents are eaten by young children,” the CPSC notification said. The FDA pointed out that the packaging for prescription drugs must be child-resistant in accordance with the Poison Prevention Packaging Act.

What ought to be done regarding the recalled goods?

Customers are not required to discard or return the affected Nurtec ODT to the distributor. As opposed to this, they should make sure the medications are “out of the sight and reach of children and contact Pfizer for a free child proof pouch to keep the product,” according to the CPSC.

Pfizer also mentioned that, “as an interim remedy,” the company has told pharmacists to put the blister containing the Nurtec ODT tablets in a child-resistant vial before giving new packages to patients in a statement issued to USA TODAY on Thursday.

When patients use the medication as directed for its intended usage, according to Pfizer, “no quality or safety issues nor health hazards” exist.

Leave a Comment